Valuation And Qualifying Accounts (In Thousands)

12 Months Ended

Dec. 31, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Valuation And Qualifying Accounts (In Thousands)

VALUATION AND QUALIFYING ACCOUNTS (IN THOUSANDS)



	Balance at Beginning of Period		Additions ⁽²⁾		Deductions Charged to Reserves			Balance at End of Period
Year ended December 31, 2018:
Accounts receivable allowances⁽¹⁾	$	12,060	$	229,509	$	(232,026	)	$	9,543
Rebates, fees and returns reserves⁽²⁾	$	100,702	$	270,959	$	(294,891	)	$	76,770
Valuation allowance for deferred tax assets ⁽³⁾	$	4,740	$	108,562	$	(24	)	$	113,278
Year ended December 31, 2017:
Accounts receivable allowances⁽¹⁾	$	9,533	$	168,945	$	(166,418	)	$	12,060
Rebates, fees and returns reserves⁽²⁾	$	89,466	$	255,471	$	(244,235	)	$	100,702
Valuation allowance for deferred tax assets ⁽³⁾	$	1,429	$	3,875	$	(564	)	$	4,740
Year ended December 31, 2016:
Accounts receivable allowances⁽¹⁾	$	10,783	$	122,792	$	(124,042	)	$	9,533
Rebates, fees and returns reserves⁽²⁾	$	45,162	$	186,941	$	(142,637	)	$	89,466
Valuation allowance for deferred tax assets ⁽³⁾	$	11,859	$	632	$	(11,062	)	$	1,429

________________________


⁽¹⁾	Accounts receivable allowances represent discounts and other chargebacks related to the provision of our product sales.


⁽²⁾	Additions to rebates, fees and returns reserves are recorded as a reduction of revenues.

⁽³⁾

As of December 31, 2018, we have established a valuation allowance on our net deferred tax assets other than refundable AMT credits. At December 31, 2017, our valuation allowance related primarily to certain of our state NOL and credit carryforwards. At December 31, 2016, our valuation allowance related primarily to our federal capital loss carryforward and our state NOL and credit carryforwards acquired from Lumara Health.